Inventiva Shares Rebound 18% Over One Month, Jefferies Maintains Buy Rating
The Burgundy-based biotech specializing in fibrotic and metabolic diseases extends its autumn rebound in mid-afternoon trading on a well-oriented Paris market. A price target revision was also issued this Tuesday.
A Rebound That Brings the Stock Back Above Its Short-Term Averages
Inventiva rises 1.5% to €3.38 in intraday trading, while the SBF 120 gains 1.12%.
The stock is up 18.18% over one month and 4.81% over the week, but still down 20.09% over three months. It trades above its 20-day moving average (MM20) of €3.17 (a gap of +6.62%) and its 50-day moving average (MM50) of €3.23, while the 200-day moving average (MM200) at €4.08 remains 17.16% above the current share price.
The €3.55 resistance level, close to the level broken on November 4, caps short-term gains. The move erases part of the decline recorded the day before last week, when the stock had fallen 4% on November 6.
Jefferies Cuts Price Target to €6.20 Without Changing Its Buy Rating
Jefferies lowers its price target from €7.50 to €6.20 and maintains its Buy rating on the stock. This target implies upside potential of around 83% relative to the current share price. On July 29, 2026, the group published its first-half results, with no revenue compared with €4.5 million a year earlier.
Among the risks cited on that occasion was a cash runway limited to the end of the second quarter of 2027 without additional financing.
The company also referred to the €103 million Equity offering and the €75 million financing transaction announced on June 2, 2026. Inventiva is listed on Euronext Paris and as ADSs on Nasdaq, the Paris-listed shares being eligible for the PEA.
